-
Your next patient is a healthy, fit 45-year-old nonsmoking woman. She says her menstrual periods are now less regular, and she reports having intermittent hot flashes. Newly divorced, she is now sexually active and wonders which contraceptive is right for her. What's your recommendation?
-
Use of the cervical cancer vaccine may soon expand: Merck has filed with the Food and Drug Administration (FDA) for use of Gardasil (Merck & Co.; Whitehouse Station, NJ) in use in women ages 27 through 45.
-
-
Review your patient charts for the past month. If national statistics are any indication, chances are many of those cases include a diagnosis of urinary tract infection (UTI).
-
Ask the next patient who comes in your office, "What is the most effective reversible contraceptive?" How many of them will name the intrauterine device (IUD)?
-
A study assessing Boston Scientific's (Natick, Massachusetts) EZ FilterWire to catch bits of plaque and blood clot that break loose during percutaneous coronary intervention (PCI) in patients with acute coronary syndrome has been discontinued after it failed to show that it can reduce rates of major cardiovascular complications.
-
CardioMind (Sunnyvale, California), an under-the-radar developer of coronary stents, has its eye on a specific, underserved sector of the drug-eluting stent (DES) sector: the worldwide market for vessel "scaffold" devices.
-
The Centers for Medicare & Medicaid have been especially busy in the cardiovascular sector the past few weeks, resisting coverage, or added coverage, in some areas, approving broader coverage in at least one sector.
-
One of the ongoing battles pitting "minimally invasive" against open surgical approaches is in clearing the carotid arteries to avoid stroke, or as therapy following stroke.
-
Clot-busting drug therapy, when administered to patients after a stroke, appears to work more effectively if the patient already has been on an anti-platelet medication. However, this might also increase the risk for bleeding within the brain.